Clinical characteristics of unregulated psychoactive supplement exposures: a 15-year multicenter study of kratom, phenibut, and tianeptine
Introduction Unregulated psychoactive “supplements” including kratom, phenibut, and tianeptine are readily accessible, raising concern for toxicity and dependence owing to their GABA and opioid receptor activity; however, clinical features associated with their use are poorly characterized. We describe hospital presentations and management of kratom, phenibut, and tianeptine exposures.Methods We analyzed data from the Toxicology Investigators Consortium (ToxIC) Core Registry, which prospectively collects information on patients managed by medical toxicologists (1 January 2010–31 December 2024). All cases involving kratom, phenibut, and/or tianeptine exposures were included. Demographics, exposure circumstances, clinical presentation, management, and outcomes were examined.Results We identified 152 patient encounters involving kratom (n = 97), phenibut (n = 44) and/or tianeptine (n = 11), with case counts increasing over time. Median age was 35 years (IQR 26–42 years), and 127 (83.6%) were male. Co-ingestions were common (n = 73; 48.0%) frequently involving other psychoactive supplements (n = 27; 17.8%), stimulants (n = 23; 15.1%) and/or opioids (n = 22; 14.5%). Most consultations involved intentional use (n = 131; 86.2%), including euphoria (n = 60; 39.5%), perceived therapeutic/wellness benefit (n = 18; 11.8%) and withdrawal self-management (n = 13; 8.6%). Thirty-five encounters (23.0%) resulted in intensive care admission and one patient died. Addiction treatment infrequently involved buprenorphine/naloxone (n = 15; 9.9%). At hospital discharge 16 (10.5%) patients received naloxone overdose prevention kit education and/or prescription.Discussion Psychoactive supplement exposures evaluated by medical toxicologists were associated with substantial morbidity, with nearly one-quarter requiring intensive care unit admission. Withdrawal was common, and nearly half of encounters involved co-ingestants.Conclusion Hospital presentations involving kratom, phenibut, and tianeptine increased over time, supporting recognition of these substances as emerging drugs of misuse rather than benign supplements. These findings highlight opportunities to strengthen addiction-focused care, regulatory oversight and public education.
Authors
- Jessica T. Kent (ORCID: https://orcid.org/0000-0003-4017-7479)
- Matthew Hacker Teper (ORCID: https://orcid.org/0000-0002-8764-0777)
- Yaron Finkelstein (ORCID: https://orcid.org/0000-0002-0947-3571)
- On behalf of the Toxicology Investigators Consortium
- Rachel Culbreth
Institutions
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- The Hospital for Sick Children (CA)
- American College of Medical Toxicology (US)
Publication Details
- Journal
- Clinical Toxicology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1080/15563650.2026.2761523
- Primary Topic
- Poisoning and overdose treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00